WASHINGTON: The US Food and Drug Administration (FDA) has approved a drug called SoanzXR, manufactured by the Virginia-based Sarfez Pharmaceuticals, which is owned by Indian-American Salim Shah, a media report said. The drug provides a new treatment option to people suffering from heart failure who experience constant edema, swelling in the lower limbs and abdomen, despite a loop diuretic therapy, as well as patients with chronic kidney disease", the American Bazaar media outlet reported.
Speaking the outlet on Monday, Shah said drug will hit the market in a couple of months. He added that the drug received the FDA approval on June 17 after the company had applied for the green-light in 2019. Clinical trials had commenced last year. "Soaanz is specifically formulated to reduce disproportionate urination in heart failure patients," Shah, a resident of Vienna, Virginia, told the American Bazaar.
"We believe that for many of these patients who are aged 65 and older, the new treatment option now approved by the FDA offers tremendous benefits." According to the US Centers for Disease Control and Prevention, heart failure affects nearly 1.8 per cent of the country's population, or about 5.7 million Americans.
Rare neurological disorder documented following AstraZeneca vaccine in India, England
US announces plans to allocate 55mn Covid-19 vaccine doses for global sharing
China donated 500,000 Sinopharm vaccine doses to Vietnam